Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients.

Literature DB >> 6153152

Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients.

J A Child, B Spati, S Illingworth, D Barnard, S Corbett, A V Simmons, J Stone, T S Worthy, E H Cooper.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1980 PMID： 6153152 DOI： 10.1002/1097-0142(19800115)45:2<318::aid-cncr2820450220>3.0.co;2-c

Source DB: PubMed Journal: Cancer ISSN： 0008-543X Impact factor: 6.860

Keyword Cloud
Cited

× No keyword cloud information.

20 in total

1. Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.

Authors: Jing Yang; Qing Yi
Journal: Am J Blood Res Date: 2011-06-15

2. Haptoglobin-related protein as a serum marker in malignant lymphoma.

Authors: R Epelbaum; C Shalitin; R Segal; C Valansi; I Arselan; D Faraggi; M Leviov; M Ben-Shahar; N Haim
Journal: Pathol Oncol Res Date: 1998 Impact factor: 3.201

3. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.

Authors: Felipe Samaniego; Fredrick Hagemeister; Jorge E Romaguera; Michelle A Fanale; Barbara Pro; Peter McLaughlin; M Alma Rodriguez; Sattva S Neelapu; Luis Fayad; Anas Younes; Lei Feng; Zuzana Berkova; Tamer Khashab; Lalit Sehgal; Francisco Vega-Vasquez; Larry W Kwak
Journal: Br J Haematol Date: 2015-03-31 Impact factor: 6.998

4. Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.

Authors: Yuki Nakajima; Naoto Tomita; Reina Watanabe; Yasufumi Ishiyama; Eri Yamamoto; Daisuke Ishibashi; Megumi Itabashi; Satoshi Koyama; Hiroyuki Takahashi; Ayumi Numata; Hirotaka Takasaki; Rika Kawasaki; Hideyuki Kuwabara; Masatsugu Tanaka; Chizuko Hashimoto; Katsumichi Fujimaki; Rika Sakai; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal: Med Oncol Date: 2014-08-21 Impact factor: 3.064

Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients.

1. Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.

2. Haptoglobin-related protein as a serum marker in malignant lymphoma.

3. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.

4. Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.

5. Beta 2-microglobulin in haematological malignancies.

6. Genetic recombination in human melanoma and astrocytoma cell lines involves oncogenes and growth factor genes.

7. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.

8. Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin's disease.

9. Genetic and clinical studies of serum beta 2-microglobulin levels in haematological malignancies.

10. Alteration of serum beta 2-microglobulin in oral carcinoma.